Does the media refer more to EYPT or RFL?

In the previous week, Eyepoint Pharmaceuticals and Eyepoint Pharmaceuticals both had 3 articles in the media. Eyepoint Pharmaceuticals' average media sentiment score of 0.00 beat Rafael's score of -0.37 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rafael 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts prefer RFL or BIOA?

BioAge Labs has a consensus price target of $36.57, suggesting a potential upside of 476.84%. Given BioAge Labs' stronger consensus rating and higher probable upside, analysts plainly believe BioAge Labs is more favorable than Rafael. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioAge Labs 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has better valuation and earnings, RFL or BIOA?

Rafael has higher earnings, but lower revenue than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rafael $920K 91.17 -$30.52M -$0.68 N/A BioAge Labs $8.99M 32.37 -$80.61M -$2.38 N/A

Is RFL or BIOA more profitable?

BioAge Labs has a net margin of -912.26% compared to Rafael's net margin of -3,321.74%. BioAge Labs' return on equity of -28.99% beat Rafael's return on equity. Company Net Margins Return on Equity Return on Assets Rafael -3,321.74% -41.27% -35.32% BioAge Labs -912.26% -28.99% -27.09%

Does the media prefer RFL or BIOA?

In the previous week, Rafael had 1 more articles in the media than BioAge Labs. MarketBeat recorded 3 mentions for Rafael and 2 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.00 beat Rafael's score of -0.37 indicating that BioAge Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rafael 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ACB or RFL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ACB or RFL more profitable?

Aurora Cannabis has a net margin of -32.26% compared to Rafael's net margin of -3,321.74%. Aurora Cannabis' return on equity of 4.37% beat Rafael's return on equity. Company Net Margins Return on Equity Return on Assets Aurora Cannabis -32.26% 4.37% 3.45% Rafael -3,321.74% -41.27% -35.32%

Does the media refer more to ACB or RFL?

In the previous week, Aurora Cannabis had 22 more articles in the media than Rafael. MarketBeat recorded 25 mentions for Aurora Cannabis and 3 mentions for Rafael. Aurora Cannabis' average media sentiment score of 0.15 beat Rafael's score of -0.37 indicating that Aurora Cannabis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurora Cannabis 4 Very Positive mention(s) 6 Positive mention(s) 6 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral Rafael 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend VNDA or RFL?

Vanda Pharmaceuticals presently has a consensus target price of $13.08, suggesting a potential upside of 186.29%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Vanda Pharmaceuticals is more favorable than Rafael. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vanda Pharmaceuticals 2 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.44 Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to VNDA or RFL?

In the previous week, Vanda Pharmaceuticals had 5 more articles in the media than Rafael. MarketBeat recorded 8 mentions for Vanda Pharmaceuticals and 3 mentions for Rafael. Vanda Pharmaceuticals' average media sentiment score of 0.35 beat Rafael's score of -0.37 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rafael 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend PALI or RFL?

Palisade Bio currently has a consensus price target of $9.29, indicating a potential upside of 502.97%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts clearly believe Palisade Bio is more favorable than Rafael. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palisade Bio 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.00 Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, PALI or RFL?

Palisade Bio has higher earnings, but lower revenue than Rafael. Palisade Bio is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Palisade Bio $250K 1,073.50 -$16.78M -$0.48 N/A Rafael $920K 91.17 -$30.52M -$0.68 N/A

Is PALI or RFL more profitable?

Palisade Bio has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Palisade Bio's return on equity of -33.47% beat Rafael's return on equity. Company Net Margins Return on Equity Return on Assets Palisade Bio N/A -33.47% -31.79% Rafael -3,321.74% -41.27% -35.32%

Does the media refer more to PALI or RFL?

In the previous week, Palisade Bio had 2 more articles in the media than Rafael. MarketBeat recorded 5 mentions for Palisade Bio and 3 mentions for Rafael. Palisade Bio's average media sentiment score of 0.34 beat Rafael's score of -0.37 indicating that Palisade Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rafael 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Rafael (RFL) Competitors

$1.61 +0.13 (+8.99%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$1.59 -0.02 (-1.43%)

As of 10/9/2026 07:30 PM Eastern

Compare

RFL vs. EYPT, BIOA, ACB, VNDA, and PALI

Should you buy Rafael stock or one of its competitors? Rafael's main competitors and comparable companies include Eyepoint Pharmaceuticals (EYPT), BioAge Labs (BIOA), Aurora Cannabis (ACB), Vanda Pharmaceuticals (VNDA), and Palisade Bio (PALI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Rafael compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Rafael has lower revenue, but higher earnings than Eyepoint Pharmaceuticals. Rafael is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$2.79M	105.14	-$231.96M	-$3.74	N/A
Rafael	$920K	91.17	-$30.52M	-$0.68	N/A

Eyepoint Pharmaceuticals currently has a consensus price target of $25.70, suggesting a potential upside of 655.88%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Rafael.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Eyepoint Pharmaceuticals and Eyepoint Pharmaceuticals both had 3 articles in the media. Eyepoint Pharmaceuticals' average media sentiment score of 0.00 beat Rafael's score of -0.37 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rafael	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Eyepoint Pharmaceuticals has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market. Comparatively, Rafael has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 11.3% of Rafael shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 32.9% of Rafael shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Rafael has a net margin of -3,321.74% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Rafael's return on equity of -41.27% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Rafael	-3,321.74%	-41.27%	-35.32%

Summary

Eyepoint Pharmaceuticals beats Rafael on 9 of the 15 factors compared between the two stocks.

How does Rafael compare to BioAge Labs?

Rafael (NYSE:RFL) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

11.3% of Rafael shares are owned by institutional investors. 32.9% of Rafael shares are owned by insiders. Comparatively, 17.6% of BioAge Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Rafael has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, BioAge Labs has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

BioAge Labs has a consensus price target of $36.57, suggesting a potential upside of 476.84%. Given BioAge Labs' stronger consensus rating and higher probable upside, analysts plainly believe BioAge Labs is more favorable than Rafael.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Rafael had 1 more articles in the media than BioAge Labs. MarketBeat recorded 3 mentions for Rafael and 2 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.00 beat Rafael's score of -0.37 indicating that BioAge Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rafael	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rafael has higher earnings, but lower revenue than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rafael	$920K	91.17	-$30.52M	-$0.68	N/A
BioAge Labs	$8.99M	32.37	-$80.61M	-$2.38	N/A

BioAge Labs has a net margin of -912.26% compared to Rafael's net margin of -3,321.74%. BioAge Labs' return on equity of -28.99% beat Rafael's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rafael	-3,321.74%	-41.27%	-35.32%
BioAge Labs	-912.26%	-28.99%	-27.09%

Summary

BioAge Labs beats Rafael on 9 of the 16 factors compared between the two stocks.

How does Rafael compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Rafael has lower revenue, but higher earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	$247.82M	1.19	-$88.13M	-$1.41	N/A
Rafael	$920K	91.17	-$30.52M	-$0.68	N/A

Aurora Cannabis has a net margin of -32.26% compared to Rafael's net margin of -3,321.74%. Aurora Cannabis' return on equity of 4.37% beat Rafael's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-32.26%	4.37%	3.45%
Rafael	-3,321.74%	-41.27%	-35.32%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

47.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 11.3% of Rafael shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by insiders. Comparatively, 32.9% of Rafael shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Aurora Cannabis has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market. Comparatively, Rafael has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

In the previous week, Aurora Cannabis had 22 more articles in the media than Rafael. MarketBeat recorded 25 mentions for Aurora Cannabis and 3 mentions for Rafael. Aurora Cannabis' average media sentiment score of 0.15 beat Rafael's score of -0.37 indicating that Aurora Cannabis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurora Cannabis	4 Very Positive mention(s)	6 Positive mention(s)	6 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral
Rafael	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Aurora Cannabis beats Rafael on 10 of the 15 factors compared between the two stocks.

How does Rafael compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 11.3% of Rafael shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 32.9% of Rafael shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Vanda Pharmaceuticals has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Rafael has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

In the previous week, Vanda Pharmaceuticals had 5 more articles in the media than Rafael. MarketBeat recorded 8 mentions for Vanda Pharmaceuticals and 3 mentions for Rafael. Vanda Pharmaceuticals' average media sentiment score of 0.35 beat Rafael's score of -0.37 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rafael	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Rafael has lower revenue, but higher earnings than Vanda Pharmaceuticals. Rafael is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$215.72M	1.28	-$220.47M	-$4.63	N/A
Rafael	$920K	91.17	-$30.52M	-$0.68	N/A

Vanda Pharmaceuticals has a net margin of -127.41% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
Rafael	-3,321.74%	-41.27%	-35.32%

Vanda Pharmaceuticals presently has a consensus target price of $13.08, suggesting a potential upside of 186.29%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Vanda Pharmaceuticals is more favorable than Rafael.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Vanda Pharmaceuticals beats Rafael on 11 of the 16 factors compared between the two stocks.

How does Rafael compare to Palisade Bio?

Palisade Bio (NASDAQ:PALI) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Palisade Bio has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Palisade Bio's return on equity of -33.47% beat Rafael's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-33.47%	-31.79%
Rafael	-3,321.74%	-41.27%	-35.32%

Palisade Bio currently has a consensus price target of $9.29, indicating a potential upside of 502.97%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts clearly believe Palisade Bio is more favorable than Rafael.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Palisade Bio has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market. Comparatively, Rafael has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

In the previous week, Palisade Bio had 2 more articles in the media than Rafael. MarketBeat recorded 5 mentions for Palisade Bio and 3 mentions for Rafael. Palisade Bio's average media sentiment score of 0.34 beat Rafael's score of -0.37 indicating that Palisade Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rafael	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

11.8% of Palisade Bio shares are owned by institutional investors. Comparatively, 11.3% of Rafael shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by insiders. Comparatively, 32.9% of Rafael shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Palisade Bio has higher earnings, but lower revenue than Rafael. Palisade Bio is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,073.50	-$16.78M	-$0.48	N/A
Rafael	$920K	91.17	-$30.52M	-$0.68	N/A

Summary

Palisade Bio beats Rafael on 14 of the 17 factors compared between the two stocks.

Get Rafael News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RFL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RFL vs. The Competition

Export

Metric	Rafael	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$76.96M	$12.32B	$7.16B	$22.94B
Dividend Yield	N/A	2.64%	2.53%	3.72%
P/E Ratio	-2.37	797.58	274.15	28.60
Price / Sales	91.17	939.82	635.98	15.12
Price / Cash	N/A	85.97	76.38	37.72
Price / Book	0.84	10.71	11.21	4.72
Net Income	-$30.52M	$2.84B	$3.50B	$1.07B
7 Day Performance	5.36%	-0.93%	-0.90%	0.35%
1 Month Performance	-32.43%	-4.91%	-4.44%	-2.93%
1 Year Performance	20.82%	-4.13%	6.96%	9.26%

Rafael Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RFL Rafael	0.7233 of 5 stars	$1.61 +9.0%	N/A	+19.5%	$76.96M	$920K	N/A	23
EYPT Eyepoint Pharmaceuticals	2.4243 of 5 stars	$3.42 -1.3%	$25.70 +652.3%	-75.7%	$295.27M	$31.37M	N/A	214
BIOA BioAge Labs	2.4827 of 5 stars	$6.41 +3.2%	$36.57 +470.5%	+16.3%	$293.99M	$8.99M	N/A	62	News Coverage Analyst Downgrade
ACB Aurora Cannabis	1.1607 of 5 stars	$4.48 +1.0%	N/A	-26.9%	$293.92M	$314.07M	N/A	1,028	Trending News
VNDA Vanda Pharmaceuticals	3.7302 of 5 stars	$4.56 +0.6%	$13.08 +187.2%	-16.1%	$275.40M	$216.10M	N/A	533	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RFL) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rafael (RFL) Competitors

RFL vs. EYPT, BIOA, ACB, VNDA, and PALI

How does Rafael compare to Eyepoint Pharmaceuticals?

Summary

How does Rafael compare to BioAge Labs?

Summary

How does Rafael compare to Aurora Cannabis?

Summary

How does Rafael compare to Vanda Pharmaceuticals?

Summary

How does Rafael compare to Palisade Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RFL vs. The Competition

Rafael Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rafael (RFL) Competitors

RFL vs. EYPT, BIOA, ACB, VNDA, and PALI

How does Rafael compare to Eyepoint Pharmaceuticals?

Which has higher valuation and earnings, EYPT or RFL?

Do analysts rate EYPT or RFL?

Does the media refer more to EYPT or RFL?

Which has more volatility and risk, EYPT or RFL?

Do insiders & institutionals hold more shares of EYPT or RFL?

Is EYPT or RFL more profitable?

Summary

How does Rafael compare to BioAge Labs?

Do institutionals & insiders hold more shares of RFL or BIOA?

Which has more volatility and risk, RFL or BIOA?

Do analysts prefer RFL or BIOA?

Does the media prefer RFL or BIOA?

Which has better valuation and earnings, RFL or BIOA?

Is RFL or BIOA more profitable?

Summary

How does Rafael compare to Aurora Cannabis?

Which has stronger valuation & earnings, ACB or RFL?

Is ACB or RFL more profitable?

Do analysts recommend ACB or RFL?

Do institutionals and insiders have more ownership in ACB or RFL?

Which has more volatility and risk, ACB or RFL?

Does the media refer more to ACB or RFL?

Summary

How does Rafael compare to Vanda Pharmaceuticals?

Do insiders & institutionals believe in VNDA or RFL?

Which has more volatility & risk, VNDA or RFL?

Does the media refer more to VNDA or RFL?

Which has better valuation & earnings, VNDA or RFL?

Is VNDA or RFL more profitable?

Do analysts recommend VNDA or RFL?

Summary

How does Rafael compare to Palisade Bio?

Is PALI or RFL more profitable?

Do analysts recommend PALI or RFL?

Which has more volatility and risk, PALI or RFL?

Does the media refer more to PALI or RFL?

Do insiders and institutionals have more ownership in PALI or RFL?

Which has preferable valuation & earnings, PALI or RFL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RFL vs. The Competition

Rafael Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools